The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 787,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in pharma: oncolytic adenovirus vectorsBuy the report here.

Smarter leaders trust GlobalData

According to GlobalData’s Technology Foresights, which uses over 668,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.

Oncolytic adenovirus vectors is a key innovation area in immuno-oncology

Oncolytic adenovirus vectors are genetically modified adenoviruses that preferentially target and kill neoplastic (cancerous) cells while sparing normal cells. The viral genome is modified by replacing the endogenous promoters in the E1A and/or E4 regions with cancer-specific promoters. These viral vectors have shown efficacy in the treatment of various types of cancer and are being tested in clinical trials.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies.  According to GlobalData, there are 60+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of oncolytic adenovirus vectors.

Key players in oncolytic adenovirus vectors – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.   

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.  

Patent volumes related to oncolytic adenovirus vectors

Company Total patents (2021 - 2023) Premium intelligence on the world's largest companies
Akamis Bio 246 Unlock Company Profile
Targovax 77 Unlock Company Profile
EpicentRx 66 Unlock Company Profile
Vascular Biogenics 57 Unlock Company Profile
DNAtrix 53 Unlock Company Profile
Genemedicine 46 Unlock Company Profile
Valo Therapeutics 35 Unlock Company Profile
Johnson & Johnson 32 Unlock Company Profile
Hangzhou Converd 31 Unlock Company Profile
TILT Biotherapeutics 28 Unlock Company Profile
CG Oncology 27 Unlock Company Profile
BioLineRx 21 Unlock Company Profile
Momotaro-Gene 21 Unlock Company Profile
Mayo Clinic 18 Unlock Company Profile
Ixogen 18 Unlock Company Profile
Coastar Therapeutics 14 Unlock Company Profile
Beijing Bio-Targeting Therapeutics Technology 13 Unlock Company Profile
Bayer 11 Unlock Company Profile
Merck 11 Unlock Company Profile
Memorial Sloan Kettering Cancer Center 11 Unlock Company Profile
Samyang 11 Unlock Company Profile
Curigin 11 Unlock Company Profile
Bionoxx 11 Unlock Company Profile
SpyBiotech 10 Unlock Company Profile
Theriva Biologics 10 Unlock Company Profile
Shanghai Yuansong Biotechnology 9 Unlock Company Profile
Trieza Therapeutics 8 Unlock Company Profile
Oncolys BioPharma 8 Unlock Company Profile
Ansun Biopharma 8 Unlock Company Profile
Mesoblast 8 Unlock Company Profile
National Cancer Center 8 Unlock Company Profile
Unleash Immuno Oncolytics 7 Unlock Company Profile
ORCA Therapeutics 7 Unlock Company Profile
Erasmus MC 7 Unlock Company Profile
Cedars-Sinai Health System 6 Unlock Company Profile
Memgen 6 Unlock Company Profile
UAB Research Foundation 5 Unlock Company Profile
Bayer Pharma (Bayer Schering Pharma) 5 Unlock Company Profile
Hubei Soundny Biotechnology 5 Unlock Company Profile
Amgen 5 Unlock Company Profile
Oncolytics Biotech 4 Unlock Company Profile
Taipei Veterans General Hospital 4 Unlock Company Profile
ARCH Development 3 Unlock Company Profile
Oncos Therapeutics 3 Unlock Company Profile
Health Access Network 3 Unlock Company Profile
SYNIMMUNE 3 Unlock Company Profile
NEW HOPE, CITY OF 2 Unlock Company Profile
MultiVir 2 Unlock Company Profile
DevaCell 2 Unlock Company Profile
Mendus 2 Unlock Company Profile

Source: GlobalData Patent Analytics

Akamis Bio, formerly PsiOxus Therapeutics, is one of the leading patent filers in oncolytic adenovirus vectors. The company develops and discovers novel therapies for the treatment of cancer and other related diseases. It utilizes T-SIGn, a tumor-specific immuno gene platform to develop gene therapies for primary and metastatic solid tumors. Its platform has capabilities to be used in combination with CAR-T and other cell therapies to overcome poor immune cell infiltration, immunosuppressive properties of tumor microenvironment, and systematic toxicity issues. Akamis Bio's product pipeline includes NG-350A and NG-641 to treat metastatic and advanced epithelial tumors. Targovax ASA and EpicentRx Inc are some of the other key patent filers in oncolytic adenovirus vectors.

In terms of application diversity, DNAtrix leads the pack, while EpicentRx and Shanghai Yuansong Biotechnology stood in the second and third positions, respectively. By means of geographic reach, Vascular Biogenics held the top position, followed by BioLineRx and Ixogen.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Immuno-oncology (IO).

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.